{"id":25235,"date":"2024-04-03T14:59:40","date_gmt":"2024-04-03T14:59:40","guid":{"rendered":"https:\/\/dupmecp2.eu\/?p=25235"},"modified":"2025-07-23T10:39:41","modified_gmt":"2025-07-23T08:39:41","slug":"huidagene-essais-cliniques","status":"publish","type":"post","link":"https:\/\/dupmecp2.eu\/el\/huidagene-essais-cliniques\/","title":{"rendered":"HuidaGene: vers les essais cliniques"},"content":{"rendered":"<p>En f\u00e9vrier 2024, David Covini, pr\u00e9sident de DupMECP2, a visit\u00e9 l&rsquo;entreprise de biotechnologie HuidaGene Therapeutics \u00e0 Shanghai. Cette visite a \u00e9t\u00e9 une occasion unique de rencontrer une \u00e9quipe dynamique dont le candidat clinique peut r\u00e9volutionner l&rsquo;avenir du traitement du syndrome de duplication du g\u00e8ne MECP2 (MDS).&nbsp;<\/p>\n\n\n\n<p>Dirig\u00e9e par le Dr. Alvin Luk, PDG de HuidagGene, l\u00b4entreprise est \u00e0 la pointe du d\u00e9veloppement d&rsquo;une technologie r\u00e9volutionnaire qui pourrait changer la vie des enfants touch\u00e9s par MDS. La visite a \u00e9t\u00e9 une occasion incroyable de d\u00e9couvrir les installations de pointe et l&rsquo;environnement cr\u00e9atif qui favorise une telle recherche. Notamment, l&rsquo;espace de bureau comprend m\u00eame un mur d&rsquo;escalade, favorisant une atmosph\u00e8re de travail cr\u00e9ative.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1920\" height=\"1080\" src=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2024\/04\/Huidagene_visit-02.2024-edited.jpg\" alt=\"\" class=\"wp-image-25367\" srcset=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2024\/04\/Huidagene_visit-02.2024-edited.jpg 1920w, https:\/\/dupmecp2.eu\/wp-content\/uploads\/2024\/04\/Huidagene_visit-02.2024-edited-300x169.jpg 300w, https:\/\/dupmecp2.eu\/wp-content\/uploads\/2024\/04\/Huidagene_visit-02.2024-edited-1024x576.jpg 1024w, https:\/\/dupmecp2.eu\/wp-content\/uploads\/2024\/04\/Huidagene_visit-02.2024-edited-768x432.jpg 768w, https:\/\/dupmecp2.eu\/wp-content\/uploads\/2024\/04\/Huidagene_visit-02.2024-edited-1536x864.jpg 1536w\" sizes=\"(max-width: 1920px) 100vw, 1920px\" \/><\/figure>\n\n\n\n<p>Alvin et sa directrice m\u00e9dicale pour MDS, le Dr Gloria Tang, ont pr\u00e9sent\u00e9 les d\u00e9tails de la technologie d&rsquo;\u00e9dition d\u00b4ARN CRISPR CAS13 pour le syndrome de duplication du g\u00e8ne <em>MECP2<\/em>, nomm\u00e9e HG204. La qualit\u00e9 prometteuse des donn\u00e9es et les r\u00e9sultats pr\u00e9liminaires des \u00e9tudes de toxicit\u00e9 sur des primates non humains ont conduit HuidaGene \u00e0 un d\u00e9veloppement passionnant. L&rsquo;essai clinique de l&rsquo;entreprise, initialement pr\u00e9vu pour commencer au second semestre 2024, a d\u00e9j\u00e0 re\u00e7u l&rsquo;approbation du comit\u00e9 d&rsquo;\u00e9thique de deux h\u00f4pitaux, avec pour objectif d&rsquo;inclure des patients atteints de MDS avant la fin de l&rsquo;ann\u00e9e.<\/p>\n\n\n\n<p>C&rsquo;est une excellente nouvelle pour la communaut\u00e9 MDS. L&rsquo;essai clinique \u00e0 venir de HG204 pour le MDS, appel\u00e9 \u00ab\u00a0HERO\u00a0\u00bb, traitera initialement au moins 4 patients qui seront \u00e9troitement surveill\u00e9s pendant un an. La premi\u00e8re phase de cet essai r\u00e9volutionnaire sera men\u00e9e en Chine. L&rsquo;inclusion de nouveaux patients en Chine d\u00e9pendra des premiers r\u00e9sultats pr\u00e9liminaires de l&rsquo;\u00e9tude interventionnelle.<\/p>\n\n\n\n<p>HuidaGene a d\u00e9j\u00e0 fait des progr\u00e8s significatifs dans l&rsquo;approbation r\u00e9glementaire, en obtenant deux d\u00e9signations de la FDA (d\u00e9signation de maladie p\u00e9diatrique rare (RPDD) et d\u00e9signation de m\u00e9dicament orphelin (ODD)) pour HG204. Ils ont \u00e9galement initi\u00e9 un contact avec la FDA et l&rsquo;EMA pour des \u00e9tudes suppl\u00e9mentaires aux \u00c9tats-Unis et en Europe.&nbsp;<\/p>\n\n\n\n<p>C&rsquo;est un privil\u00e8ge d&rsquo;avoir eu l&rsquo;occasion de rencontrer en personne Alvin et Gloria. Nous sommes ravis de participer \u00e0 cette aventure et nous sommes impatients de tenir notre communaut\u00e9 inform\u00e9e des progr\u00e8s de cette technologie qui pourrait changer la vie.<\/p>\n\n\n\n<p><\/p>","protected":false},"excerpt":{"rendered":"<p>En f\u00e9vrier 2024, David Covini, pr\u00e9sident de DupMECP2, a visit\u00e9 l&rsquo;entreprise de biotechnologie HuidaGene Therapeutics \u00e0 Shanghai. Cette visite a \u00e9t\u00e9 une occasion unique de rencontrer une \u00e9quipe dynamique dont [&hellip;]<\/p>","protected":false},"author":1,"featured_media":25367,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-25235","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualite"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>HuidaGene: vers les essais cliniques - DupMECP2<\/title>\n<meta name=\"description\" content=\"En f\u00e9vrier 2024, David Covini, pr\u00e9sident de DupMECP2, a visit\u00e9 l&#039;entreprise de biotechnologie HuidaGene Therapeutics \u00e0 Shanghai. Cette visite a \u00e9t\u00e9 une occasion unique de rencontrer une \u00e9quipe dynamique dont le candidat clinique peut r\u00e9volutionner l&#039;avenir du traitement du syndrome de duplication du g\u00e8ne MECP2 (MDS).\u00a0\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dupmecp2.eu\/el\/huidagene-essais-cliniques\/\" \/>\n<meta property=\"og:locale\" content=\"el_GR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HuidaGene: vers les essais cliniques - DupMECP2\" \/>\n<meta property=\"og:description\" content=\"En f\u00e9vrier 2024, David Covini, pr\u00e9sident de DupMECP2, a visit\u00e9 l&#039;entreprise de biotechnologie HuidaGene Therapeutics \u00e0 Shanghai. Cette visite a \u00e9t\u00e9 une occasion unique de rencontrer une \u00e9quipe dynamique dont le candidat clinique peut r\u00e9volutionner l&#039;avenir du traitement du syndrome de duplication du g\u00e8ne MECP2 (MDS).\u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dupmecp2.eu\/el\/huidagene-essais-cliniques\/\" \/>\n<meta property=\"og:site_name\" content=\"DupMECP2\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-03T14:59:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-23T08:39:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2024\/04\/Huidagene_visit-02.2024-edited.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Caroline\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caroline\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 \u03bb\u03b5\u03c0\u03c4\u03ac\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/\"},\"author\":{\"name\":\"Caroline\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\"},\"headline\":\"HuidaGene: vers les essais cliniques\",\"datePublished\":\"2024-04-03T14:59:40+00:00\",\"dateModified\":\"2025-07-23T08:39:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/\"},\"wordCount\":403,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2024\/04\/Huidagene_visit-02.2024-edited.jpg\",\"articleSection\":[\"Actualit\u00e9\"],\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/\",\"url\":\"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/\",\"name\":\"HuidaGene: vers les essais cliniques - DupMECP2\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2024\/04\/Huidagene_visit-02.2024-edited.jpg\",\"datePublished\":\"2024-04-03T14:59:40+00:00\",\"dateModified\":\"2025-07-23T08:39:41+00:00\",\"description\":\"En f\u00e9vrier 2024, David Covini, pr\u00e9sident de DupMECP2, a visit\u00e9 l'entreprise de biotechnologie HuidaGene Therapeutics \u00e0 Shanghai. Cette visite a \u00e9t\u00e9 une occasion unique de rencontrer une \u00e9quipe dynamique dont le candidat clinique peut r\u00e9volutionner l'avenir du traitement du syndrome de duplication du g\u00e8ne MECP2 (MDS).\u00a0\",\"breadcrumb\":{\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#breadcrumb\"},\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#primaryimage\",\"url\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2024\/04\/Huidagene_visit-02.2024-edited.jpg\",\"contentUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2024\/04\/Huidagene_visit-02.2024-edited.jpg\",\"width\":1920,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/dupmecp2.eu\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Actualit\u00e9\",\"item\":\"https:\/\/dupmecp2.eu\/category\/actualite\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"HuidaGene: vers les essais cliniques\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dupmecp2.eu\/#website\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"name\":\"DupMECP2\",\"description\":\"EU\",\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dupmecp2.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"el\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dupmecp2.eu\/#organization\",\"name\":\"DupMECP2\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"DupMECP2\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\",\"name\":\"Caroline\",\"sameAs\":[\"https:\/\/dupmecp2.eu\"],\"url\":\"https:\/\/dupmecp2.eu\/el\/author\/417a2385dc37aa45\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HuidaGene: vers les essais cliniques - DupMECP2","description":"En f\u00e9vrier 2024, David Covini, pr\u00e9sident de DupMECP2, a visit\u00e9 l'entreprise de biotechnologie HuidaGene Therapeutics \u00e0 Shanghai. Cette visite a \u00e9t\u00e9 une occasion unique de rencontrer une \u00e9quipe dynamique dont le candidat clinique peut r\u00e9volutionner l'avenir du traitement du syndrome de duplication du g\u00e8ne MECP2 (MDS).\u00a0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dupmecp2.eu\/el\/huidagene-essais-cliniques\/","og_locale":"el_GR","og_type":"article","og_title":"HuidaGene: vers les essais cliniques - DupMECP2","og_description":"En f\u00e9vrier 2024, David Covini, pr\u00e9sident de DupMECP2, a visit\u00e9 l'entreprise de biotechnologie HuidaGene Therapeutics \u00e0 Shanghai. Cette visite a \u00e9t\u00e9 une occasion unique de rencontrer une \u00e9quipe dynamique dont le candidat clinique peut r\u00e9volutionner l'avenir du traitement du syndrome de duplication du g\u00e8ne MECP2 (MDS).\u00a0","og_url":"https:\/\/dupmecp2.eu\/el\/huidagene-essais-cliniques\/","og_site_name":"DupMECP2","article_published_time":"2024-04-03T14:59:40+00:00","article_modified_time":"2025-07-23T08:39:41+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2024\/04\/Huidagene_visit-02.2024-edited.jpg","type":"image\/jpeg"}],"author":"Caroline","twitter_card":"summary_large_image","twitter_misc":{"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc":"Caroline","\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2":"3 \u03bb\u03b5\u03c0\u03c4\u03ac"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#article","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/"},"author":{"name":"Caroline","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee"},"headline":"HuidaGene: vers les essais cliniques","datePublished":"2024-04-03T14:59:40+00:00","dateModified":"2025-07-23T08:39:41+00:00","mainEntityOfPage":{"@id":"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/"},"wordCount":403,"commentCount":0,"publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"image":{"@id":"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2024\/04\/Huidagene_visit-02.2024-edited.jpg","articleSection":["Actualit\u00e9"],"inLanguage":"el","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/","url":"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/","name":"HuidaGene: vers les essais cliniques - DupMECP2","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#primaryimage"},"image":{"@id":"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2024\/04\/Huidagene_visit-02.2024-edited.jpg","datePublished":"2024-04-03T14:59:40+00:00","dateModified":"2025-07-23T08:39:41+00:00","description":"En f\u00e9vrier 2024, David Covini, pr\u00e9sident de DupMECP2, a visit\u00e9 l'entreprise de biotechnologie HuidaGene Therapeutics \u00e0 Shanghai. Cette visite a \u00e9t\u00e9 une occasion unique de rencontrer une \u00e9quipe dynamique dont le candidat clinique peut r\u00e9volutionner l'avenir du traitement du syndrome de duplication du g\u00e8ne MECP2 (MDS).\u00a0","breadcrumb":{"@id":"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#breadcrumb"},"inLanguage":"el","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/"]}]},{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#primaryimage","url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2024\/04\/Huidagene_visit-02.2024-edited.jpg","contentUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2024\/04\/Huidagene_visit-02.2024-edited.jpg","width":1920,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/dupmecp2.eu\/huidagene-essais-cliniques\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/dupmecp2.eu\/"},{"@type":"ListItem","position":2,"name":"Actualit\u00e9","item":"https:\/\/dupmecp2.eu\/category\/actualite\/"},{"@type":"ListItem","position":3,"name":"HuidaGene: vers les essais cliniques"}]},{"@type":"WebSite","@id":"https:\/\/dupmecp2.eu\/#website","url":"https:\/\/dupmecp2.eu\/","name":"DupMECP2","description":"\u0395\u0395","publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dupmecp2.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"el"},{"@type":"Organization","@id":"https:\/\/dupmecp2.eu\/#organization","name":"DupMECP2","url":"https:\/\/dupmecp2.eu\/","logo":{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"DupMECP2"},"image":{"@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee","name":"\u039a\u03b1\u03c1\u03bf\u03bb\u03af\u03bd\u03b1","sameAs":["https:\/\/dupmecp2.eu"],"url":"https:\/\/dupmecp2.eu\/el\/author\/417a2385dc37aa45\/"}]}},"_links":{"self":[{"href":"https:\/\/dupmecp2.eu\/el\/wp-json\/wp\/v2\/posts\/25235","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dupmecp2.eu\/el\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dupmecp2.eu\/el\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/el\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/el\/wp-json\/wp\/v2\/comments?post=25235"}],"version-history":[{"count":1,"href":"https:\/\/dupmecp2.eu\/el\/wp-json\/wp\/v2\/posts\/25235\/revisions"}],"predecessor-version":[{"id":33411,"href":"https:\/\/dupmecp2.eu\/el\/wp-json\/wp\/v2\/posts\/25235\/revisions\/33411"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/el\/wp-json\/wp\/v2\/media\/25367"}],"wp:attachment":[{"href":"https:\/\/dupmecp2.eu\/el\/wp-json\/wp\/v2\/media?parent=25235"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dupmecp2.eu\/el\/wp-json\/wp\/v2\/categories?post=25235"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dupmecp2.eu\/el\/wp-json\/wp\/v2\/tags?post=25235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}